Snjezana Dogan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4744085/publications.pdf

Version: 2024-02-01

159585 110387 9,717 67 30 64 citations h-index g-index papers 67 67 67 15764 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nature Medicine, 2017, 23, 703-713.	30.7	2,473
2	Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nature Biotechnology, 2013, 31, 1023-1031.	17.5	1,785
3	Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT). Journal of Molecular Diagnostics, 2015, 17, 251-264.	2.8	1,566
4	Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. Journal of Clinical Investigation, 2016, 126, 1052-1066.	8.2	874
5	Molecular Epidemiology of <i>EGFR</i> and <i>KRAS</i> Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related <i>KRAS</i> Mutant Cancers. Clinical Cancer Research, 2012, 18, 6169-6177.	7.0	503
6	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. JAMA Oncology, 2017, 3, 244.	7.1	191
7	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer. Clinical Cancer Research, 2016, 22, 4623-4633.	7.0	153
8	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	21.4	152
9	Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid, 2020, 30, 1505-1517.	4.5	143
10	Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma. Journal of Clinical Investigation, 2019, 129, 4276-4289.	8.2	134
11	Crystal-Storing Histiocytosis: Report of a Case, Review of the Literature (80 Cases) and a Proposed Classification. Head and Neck Pathology, 2012, 6, 111-120.	2.6	129
12	Consistent PLAG1 and HMGA2 abnormalities distinguish carcinoma ex-pleomorphic adenoma from its de novo counterparts. Human Pathology, 2015, 46, 26-33.	2.0	103
13	Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of <i>MED12</i> and <i>RBM10</i> as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical Cancer Research, 2017, 23, 5970-5980.	7.0	89
14	Frequent <i>IDH2</i> R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas. Journal of Pathology, 2017, 242, 400-408.	4.5	83
15	DNA methylation-based classification of sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 1447-1459.	5.5	82
16	Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. Annals of Surgical Oncology, 2015, 22, 4411-4421.	1.5	80
17	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. Clinical Cancer Research, 2020, 26, 2859-2870.	7.0	75
18	Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6–NTRK3 fusion. Modern Pathology, 2016, 29, 985-995.	5 . 5	74

#	Article	IF	Citations
19	Human papillomavirus and Epstein–Barr virus in nasopharyngeal carcinoma in a lowâ€incidence population. Head and Neck, 2014, 36, 511-516.	2.0	71
20	Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nature Communications, 2021, 12, 3770.	12.8	68
21	<i>EIF1AX</i> and <i>RAS</i> Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. Cancer Discovery, 2019, 9, 264-281.	9.4	57
22	OncoTree: A Cancer Classification System for Precision Oncology. JCO Clinical Cancer Informatics, 2021, 5, 221-230.	2.1	51
23	Identification of prognostic molecular biomarkers in 157 HPVâ€positive and HPVâ€negative squamous cell carcinomas of the oropharynx. International Journal of Cancer, 2019, 145, 3152-3162.	5.1	48
24	Consistent copy number changes and recurrent <scp><i>PRKAR1A</i></scp> mutations distinguish <scp>M</scp> elanotic <scp>S</scp> chwannomas from <scp>M</scp> elanomas: <scp>SNP</scp> â€array and next generation sequencing analysis. Genes Chromosomes and Cancer, 2015, 54, 463-471.	2.8	44
25	Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome. Modern Pathology, 2020, 33, 1690-1701.	5.5	42
26	Primary highâ€grade nonâ€anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology, 2022, 80, 322-337.	2.9	41
27	Histologic Classification and Molecular Signature of Polymorphous Adenocarcinoma (PAC) and Cribriform Adenocarcinoma of Salivary Gland (CASG). American Journal of Surgical Pathology, 2020, 44, 545-552.	3.7	39
28	Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. Lung Cancer, 2018, 119, 85-90.	2.0	38
29	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNPH3-ALK rearrangement. Human Pathology, 2019, 88, 66-77.	2.0	38
30	Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features. Endocrine, 2019, 64, 97-108.	2.3	35
31	Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers. Scientific Reports, 2019, 9, 16830.	3.3	29
32	Feasibility of In Situ, High-Resolution Correlation of Tracer Uptake with Histopathology by Quantitative Autoradiography of Biopsy Specimens Obtained Under ¹⁸ F-FDG PET/CT Guidance. Journal of Nuclear Medicine, 2015, 56, 538-544.	5.0	28
33	Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance. Human Pathology, 2019, 93, 30-36.	2.0	27
34	Metastasis to the thyroid gland: a singleâ€institution 16â€year experience. Histopathology, 2021, 78, 508-519.	2.9	26
35	IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies. American Journal of Surgical Pathology, 2021, 45, 1190-1204.	3.7	26
36	Invasive Mucinous Adenocarcinomas With Spatially Separate Lung Lesions: Analysis of Clonal Relationship by Comparative Molecular Profiling. Journal of Thoracic Oncology, 2021, 16, 1188-1199.	1.1	23

#	Article	IF	Citations
37	Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis. Cancer Cytopathology, 2013, 121, 354-360.	2.4	22
38	The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma. Modern Pathology, 2019, 32, 205-215.	5.5	22
39	A Pan-Cancer Study of Somatic TERT Promoter Mutations and Amplification in 30,773 Tumors Profiled by Clinical Genomic Sequencing. Journal of Molecular Diagnostics, 2021, 23, 253-263.	2.8	20
40	Rapid EGFR Mutation Detection Using the Idylla Platform. Journal of Molecular Diagnostics, 2021, 23, 310-322.	2.8	19
41	Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 293-302.	2.8	16
42	A proportion of primary squamous cell carcinomas of the parotid gland harbour highâ€risk human papillomavirus. Histopathology, 2016, 69, 921-929.	2.9	15
43	Genetic basis of SMARCB1 protein loss in 22 sinonasal carcinomas. Human Pathology, 2020, 104, 105-116.	2.0	14
44	Squamous cell carcinoma of the tonsil managed by conventional surgery and postoperative radiation. Head and Neck, 2015, 37, 800-807.	2.0	13
45	Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants. Human Pathology, 2020, 106, 45-53.	2.0	13
46	Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy. Molecular Cancer Research, 2022, 20, 45-55.	3.4	13
47	Cytologic findings of mammary analogue secretory carcinoma arising in the thyroid. Diagnostic Cytopathology, 2017, 45, 552-556.	1.0	12
48	NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility. Histopathology, 2021, 79, 650-660.	2.9	12
49	Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data. Journal of Molecular Diagnostics, 2022, 24, 515-528.	2.8	12
50	Clinicopathologic features and outcome of head and neck mucosal spindle cell squamous cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 729-739.	2.8	11
51	<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology, 2021, 5, 1259-1269.	3.0	10
52	Clinicopathologic Characteristics of Young Patients with Oral Squamous Cell Carcinoma. Head and Neck Pathology, 2021, 15, 1099-1108.	2.6	9
53	Young non-smokers with oral cancer: What are we missing and why?. Oral Oncology, 2022, 127, 105803.	1.5	9
54	Technical Note: Scintillation well counters and particle counting digital autoradiography devices can be used to detect activities associated with genomic profiling adequacy of biopsy specimens obtained after a low activity ¹⁸ Fâ€ <scp>FDG</scp> injection. Medical Physics, 2018, 45, 2179-2185.	3.0	8

#	Article	IF	CITATIONS
55	ERBB2 amplification status in 67 salivary duct carcinomas assessed by immunohistochemistry, fluorescence in situ hybridization, and targeted exome sequencing. Modern Pathology, 2022, 35, 895-902.	5.5	7
56	Secretory Carcinoma of the Thyroid in a 49-Year-Old Man Treated with Larotrectinib: Protracted Clinical Course of Disease Despite the High-Grade Histologic Features. Head and Neck Pathology, 2022, 16, 612-620.	2.6	6
57	Primary Mesenchymal Tumors of the Thyroid Gland: A Modern Retrospective Cohort Including the First Case of TFE3-Translocated Malignant Perivascular Epithelioid Cell Tumor (PEComa). Head and Neck Pathology, 2022, , 1.	2.6	6
58	Prognostic impact of extranodal extension (ENE) in surgically managed treatment-naive HPV-positive oropharyngeal squamous cell carcinoma with nodal metastasis. Modern Pathology, 2022, 35, 1578-1586.	5.5	6
59	Evaluation of the tumor registration error in biopsy procedures performed under realâ€time PET/CT guidance. Medical Physics, 2017, 44, 5089-5095.	3.0	5
60	ESR1 hotspot mutations in endometrial stromal sarcoma with high-grade transformation and endocrine treatment. Modern Pathology, 2021, , .	5.5	5
61	TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas. Endocrine Pathology, 2022, 33, 304-314.	9.0	4
62	SMARCB1-deficient carcinomas of the head and neck region: a cytopathologic characterization. Journal of the American Society of Cytopathology, 2020, 9, 494-501.	0.5	3
63	Primary cutaneous SMARCB1 â€deficient carcinoma. Journal of Cutaneous Pathology, 2021, 48, 1051-1060.	1.3	3
64	Stimulated Raman Histology for Rapid <scp>Intraâ€Operative</scp> Diagnosis of Sinonasal and Skull Base Tumors. Laryngoscope, 2022, 132, 2142-2147.	2.0	2
65	Sinonasal Carcinomas. , 2020, , 197-203.		0
66	Salivary Gland Carcinomas. , 2020, , 183-195.		0
67	Extended Application of Stimulated Raman Histology in Novel Sinonasal/Skull Bases Pathologies. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, .	0.8	0